AI is rapidly moving from experimentation to real-world application in early drug discovery. But where does it truly add value for CROs and what continues to limit broader adoption?
Join us for this valuable webinar to explore how AI is being applied across early discovery, from target and molecule prioritization to experimental planning and iterative learning across Design–Make–Test–Analyze (DMTA) cycles. The discussion will examine where AI is demonstrating measurable scientific value, how it complements expert judgment, and the practical challenges organizations face when integrating AI into discovery workflows.
Drawing on hands-on experience across multiple discovery environments, we’ll highlight operational and organizational considerations relevant to CROs, including data fragmentation, governance, workflow integration, and change management. You’ll learn about:
Don’t miss key insights on how to approach AI adoption in early discovery and what it takes to integrate AI more effectively into scientific workflows. Register today!
Dr. Subhendu Kumar Mohanty is Vice President and Head of Chemistry at Syngene International, and a seasoned leader in drug discovery with over 18 years of continuous experience. A long-standing contributor to Syngene’s growth, he has held key leadership roles including Head of Medicinal Chemistry, Head of SynVent Operations, and Head of Alliance Management for discovery services. His expertise spans synthetic and medicinal chemistry, with a strong track record across multiple drug discovery modalities. Known for his strategic thinking and collaborative leadership, he has played a pivotal role in advancing integrated research programs. Dr. Mohanty holds a PhD in Organic Chemistry from IIT Madras and completed postdoctoral research in Biophysical Sciences at NCBS, Bangalore.
